Purified antithrombin supplementation in coronary revascularisation operations

European Journal of Anaesthesiology

Volumn 24, Issue SUPPL. 40, 2007, Pages 71-76

  Rossi, M ^a,d   Soro, G ^b   Schiavello, R ^b   Guarneri, S ^c  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS Policlinico S Donato   (Italy)

^c Catholic University   (Spain)

^d IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Antithrombin; Cardiopulmonary bypass; Complications; Surgery

Indexed keywords

ANBIN; ANTITHROMBIN; CISATRACURIUM; HEPARIN; MIDAZOLAM; PROPOFOL; PROTAMINE; REMIFENTANIL; SEVOFLURANE; SUFENTANIL; UNCLASSIFIED DRUG; VECURONIUM;

ADULT; ARTICLE; BLEEDING TENDENCY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CONVALESCENCE; CORONARY ARTERY SURGERY; FEMALE; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; RETROSPECTIVE STUDY; SCORING SYSTEM; SURGICAL PATIENT; THROMBOSIS;

EID: 34447530594     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1017/S0265021507000646     Document Type: Article

References (16)

1. Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 1995; 58: 799-805.
2. Ranucci M, Cazzaniga A, Soro G, Isgrò G, Frigiola A, Menicanti L. The antithrombin III-saving effect of reduced systemic heparinization and heparin-coated circuits. J Cardiothorac Vasc Anesth 2002; 16: 316-320.
3. Ranucci M, Ditta A, Boncilli A et al. Determinants of antithrombin consumption in cardiac operations requiring cardiopulmonary bypass. Perfusion 2004; 19: 47-52.
4. Despotis GJ, Levine V, Joist JH, Joiner-Maier D, Spitznagel E. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg 1997; 85: 498-506.
5. DietrichW, Spannagl M, SchrammW, VogtW, Barankay A, Richter JA. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 102: 505-514.
6. Ranucci M, Isgro G, Cazzaniga A et al. Different patterns of heparin resistance: therapeutic implications. Perfusion 2002; 17: 199-204.
7. Ranucci M, Isgro G, Cazzaniga A, Soro G, Menicanti L, Frigiola A. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion 1999; 14: 437-442.
8. Levy JH, Despotis GJ, Szlam F, Olson P, Meeker D, Weisinger A. Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. Anesthesiology 2002; 96: 1095-1102.
9. Levy JH, Montes F, Szlam F, Hillyer C. In vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 2000; 90: 1076-1079.
10. Lemmer JH, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002; 123: 213-217.
11. Koster A, Chew D, Kuebler W, Habazettl H, Hetzer R, Kuppe H. High antithrombin III levels attenuate hemostatic activation and leukocyte activation during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2003; 126: 906-907.
12. Rossi M, Martinelli L, Storti S et al. The role of antithrombin III in the perioperative management of the patient with unstable angina. Ann Thorac Surg 1999; 68: 2231-2236.
13. Ranucci M, Frigiola A, Menicanti L, Ditta A, Boncilli A, Brozzi S. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 2005; 33: 355-360.
14. Slaughter TF, Mark JB, El-Moalem H et al. Hemostatic effects of antithrombin III supplementation during cardiac surgery: results of a prospective randomized investigation. Blood Coagul Fibrinolysis 2001; 12: 25-31.
15. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001; 86: 51-56.
16. Warren BL, Eid A, Singer P et al. KyberSept Trial Study Group. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-1878.